跳至主要内容
临床试验/NCT02390037
NCT02390037已完成不适用

Pipeline™ Flex Embolization Device With Shield Technology™ Clinical Study

Medtronic Neurovascular Clinical Affairs7 个研究点 分布在 6 个国家目标入组 50 人开始时间: 2015年3月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
50
试验地点
7
主要终点
Occurrence of major stroke or neurological death

研究概览

简要总结

The objective of the study is to assess the incidence of safety outcomes in patients treated with Pipeline™ Flex embolization device with Shield Technology™.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subject has provided written informed consent using the IRB/EC-approved consent form and agrees to comply with protocol requirements.
  • Age 18-80 years.
  • Subject has already been selected for flow diversion therapy as the appropriate treatment.
  • Subject has an unruptured target intracranial aneurysm (IA).
  • Subject has a target IA located in the anterior or posterior circulation.

排除标准

  • Major surgery in the past 30 days.
  • Any known contraindication to treatment with the Pipeline™ Flex embolization device with Shield Technology™ per Instructions for Use.
  • Pregnant or breast-feeding women or women who wish to become pregnant during the length of study participation.

结局指标

主要结局

Occurrence of major stroke or neurological death

时间窗: 1 year

次要结局

  • Device related neurologic adverse event rate(1 year)

研究者

发起方
Medtronic Neurovascular Clinical Affairs
申办方类型
Industry
责任方
Sponsor

研究点 (7)

Loading locations...

相似试验